DBV Technologies (NASDAQ:DBVT) Stock Price Up 7.2% – Here’s What Happened

DBV Technologies S.A. (NASDAQ:DBVT) shares were up 7.2% on Friday . The stock traded as high as $17.00 and last traded at $17.20. Approximately 6,160 shares were traded during trading, a decline of 98% from the average daily volume of 289,443 shares. The stock had previously closed at $16.04.

Analyst Ratings Changes

A number of equities analysts have recently commented on DBVT shares. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Citizens Jmp increased their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research report on Friday, May 1st. Finally, Guggenheim reissued a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, DBV Technologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Trading Up 5.0%

The company has a fifty day moving average of $19.48 and a two-hundred day moving average of $19.65. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -3.90 and a beta of -0.99.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). The firm had revenue of $0.90 million for the quarter, compared to the consensus estimate of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. As a group, sell-side analysts predict that DBV Technologies S.A. will post -0.47 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

Several institutional investors have recently added to or reduced their stakes in DBVT. MPM Bioimpact LLC bought a new stake in shares of DBV Technologies during the 2nd quarter worth $9,649,000. Adage Capital Partners GP L.L.C. bought a new position in shares of DBV Technologies in the second quarter valued at approximately $9,659,000. Octagon Capital Advisors LP bought a new stake in DBV Technologies during the second quarter worth $9,315,000. New York State Common Retirement Fund bought a new stake in shares of DBV Technologies in the third quarter valued at $34,000. Finally, Artisan Partners Limited Partnership purchased a new position in shares of DBV Technologies in the third quarter valued at $519,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.